Article
Pharmacovigilance analysis of inclisiran:a real-world assessment based on the FAERS database
2025-03-06
Abstract excerpt
<h4>Background: </h4> :Inclisiran, a novel small interfering RNA (siRNA) therapy targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), has demonstrated efficacy in lowering low-density lipoprotein cholesterol (LDL-C). While generally well-tolerated, emerging evidence has highlighted safety concerns, particularly joint-related adverse events (AEs), such as arthralgia. atorvastatin, a commonly prescribed...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1113137b-a2cb-5da6-b699-13fdc16f79e2
- DOI
- 10.22541/au.174127529.93210053/v1
